All In MedTech

Device Trial Radar · NCT02736825

Simulines Non-Inferiority Pivotal Study

Non-Inferiority Study of the Safety and Efficacy of Ultherapy® Using Standard Versus Simulines Transducers at a Reduced Energy Level for Patient Comfort

Last checked: Nov 20, 2026Latest source record: Feb 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingTitle says "pivotal". Randomized with 262 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

262

Actual

Start

Apr 11, 2016

Primary completion

Jan 20, 2017

Study completion Apr 25, 2017

Sponsor

Lead sponsor
Ulthera, IncNot on our public-company list
Sponsor type
Industry
First posted
Apr 13, 2016

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 30 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Up to 260 subjects presenting with skin laxity on the face and neck will be randomized to one of two treatment groups. Subjects meeting all entrance criteria will receive study treatment, then complete two post treatment phone contacts and follow-up study visits at 90, 180 and 365 days post treatment. Study images will be obtained pre-treatment, immediately post-treatment, and at each follow-up visit for qualitative and quantitative assessments of efficacy.

Conditions

  • Skin Laxity

Interventions

  • Ulthera System with standard transducerDevice

    Focused ultrasound energy delivered below the surface of the skin using commercially available transducer to deliver one line of treatment at a time

  • Ulthera System with prototype 2 simulines transducerDevice

    Focused ultrasound energy delivered below the surface of the skin using new transducer to deliver two lines of treatment simultaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Achieved Greater Than or Equal to (>=) 20 mm^2 Reduction in Submental Area at Day 90Time frame: Day 90

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Testing of Beverly Hills

    Beverly Hills, California

  • Roseville Facial Plastic Surgery

    Roseville, California

  • Laser and Skin Surgery Center

    Sacramento, California

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.